Logo image of KAPA

KAIROS PHARMA LTD (KAPA) Stock Fundamental Analysis

NYSEARCA:KAPA - NYSE Arca - US48301N1046 - Common Stock - Currency: USD

1.33  +0.01 (+0.76%)

After market: 1.3 -0.03 (-2.26%)

Fundamental Rating

1

KAPA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. KAPA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. KAPA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KAPA has reported negative net income.
KAPA Yearly Net Income VS EBIT VS OCF VS FCFKAPA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -500K -1M -1.5M -2M

1.2 Ratios

The Return On Assets of KAPA (-54.78%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -82.26%, KAPA is in line with its industry, outperforming 51.33% of the companies in the same industry.
Industry RankSector Rank
ROA -54.78%
ROE -82.26%
ROIC N/A
ROA(3y)-188.63%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KAPA Yearly ROA, ROE, ROICKAPA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 100 -100 -200

1.3 Margins

KAPA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KAPA Yearly Profit, Operating, Gross MarginsKAPA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for KAPA remains at a similar level compared to 1 year ago.
The debt/assets ratio for KAPA is higher compared to a year ago.
KAPA Yearly Shares OutstandingKAPA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2M 4M 6M 8M 10M
KAPA Yearly Total Debt VS Total AssetsKAPA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 200K 400K 600K 800K 1M

2.2 Solvency

KAPA has an Altman-Z score of 3.78. This indicates that KAPA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of KAPA (3.78) is better than 76.91% of its industry peers.
KAPA has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, KAPA is doing worse than 62.52% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z 3.78
ROIC/WACCN/A
WACCN/A
KAPA Yearly LT Debt VS Equity VS FCFKAPA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 500K -500K -1M -1.5M -2M

2.3 Liquidity

A Current Ratio of 2.84 indicates that KAPA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.84, KAPA is doing worse than 67.85% of the companies in the same industry.
A Quick Ratio of 2.84 indicates that KAPA has no problem at all paying its short term obligations.
KAPA's Quick ratio of 2.84 is on the low side compared to the rest of the industry. KAPA is outperformed by 65.36% of its industry peers.
Industry RankSector Rank
Current Ratio 2.84
Quick Ratio 2.84
KAPA Yearly Current Assets VS Current LiabilitesKAPA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

KAPA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -72.58%.
EPS 1Y (TTM)-72.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KAPA will show a very negative growth in Earnings Per Share. The EPS will decrease by -48.17% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y27.71%
EPS Next 2Y-28.94%
EPS Next 3Y-48.17%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KAPA Yearly Revenue VS EstimatesKAPA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026
KAPA Yearly EPS VS EstimatesKAPA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.1 -0.2 -0.3 -0.4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KAPA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KAPA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KAPA Price Earnings VS Forward Price EarningsKAPA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KAPA Per share dataKAPA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2

4.3 Compensation for Growth

KAPA's earnings are expected to decrease with -48.17% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.94%
EPS Next 3Y-48.17%

More info and screens

0

5. Dividend

5.1 Amount

KAPA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KAIROS PHARMA LTD

NYSEARCA:KAPA (2/20/2025, 8:04:00 PM)

After market: 1.3 -0.03 (-2.26%)

1.33

+0.01 (+0.76%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner Change1143%
Ins Owners52.09%
Ins Owner Change0.12%
Market Cap18.22M
Analysts82.86
Price Target9.18 (590.23%)
Short Float %1.86%
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.47
P/tB 5.94
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.23
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.24
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.78%
ROE -82.26%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-188.63%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.84
Quick Ratio 2.84
Altman-Z 3.78
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-72.58%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y27.71%
EPS Next 2Y-28.94%
EPS Next 3Y-48.17%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-200.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y122.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y122.95%
OCF growth 3YN/A
OCF growth 5YN/A